NL-OMON34459
Completed
Not Applicable
A Phase 1, Dose Escalation Study to Evaluate the safety tolerability and pharmacokinetics of single oral doses of ELND007 in healthy elderly subjects. - ELND007 SAD in elderly
Elan Pharma0 sites42 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Alzheimer
- Sponsor
- Elan Pharma
- Enrollment
- 42
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy elderly volunteers, between 55 and 80 years of age, BMI is \<32 kg/m2, body weight should be \* 125 kg, non\-smoker or or used tobacco products within the last 5 years
- •\* female subjects should be at least 2 years post\-menopausal or surgically sterile (hysterectomy or sterilization);
Exclusion Criteria
- •Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 90 days from the start of the study. In case of donating more than 1\.5 liters of blood in the past 10 months prior to the start of this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A study in healthy males to assess the safety and tolerability of two different formulations of the study drug, (MSP-2017), administered intranasally.This study is for healthy volunteers. The intended use of the investigational product is to self-terminate acute episodes of paroxysmal supraventricular tachycardia (PSVT), a non-life threatening cardiac arrhythmia.Cardiovascular - Coronary heart diseaseACTRN12613000971730CPR Pharma Services48
Completed
Phase 1
A Phase I, Dose-Escalating Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Intrathecal Infusion of KP-100IT through SM-1500 in Subjects with Amyotrophic Lateral Sclerosis (ALS)Amyotrophic lateral sclerosis (ALS)JPRN-UMIN000007062Kringle Pharma, Inc.15
Active, not recruiting
Phase 1
A study to investigate the safety, tolerability and efficacy of PCI/Gemcitabine treatment followed by combination chemotherapy in patients with cholangiocarcinomasInoperable advanced cholangiocarcinomasMedDRA version: 20.0Level: LLTClassification code 10008594Term: Cholangiocarcinoma non-resectableSystem Organ Class: 100000054936Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-002888-10-GBPCI Biotech AS68
Active, not recruiting
Phase 1
A study to investigate the safety, tolerability and efficacy of PCI/Gemcitabine treatment followed by combination chemotherapy in patients with cholangiocarcinomasInoperable advanced cholangiocarcinomasMedDRA version: 20.0 Level: LLT Classification code 10008594 Term: Cholangiocarcinoma non-resectable System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-002888-10-FRPCI Biotech AS61
Active, not recruiting
Phase 1
A study to investigate the safety, tolerability and efficacy of PCI/Gemcitabine treatment followed by combination chemotherapy in patients with cholangiocarcinomasInoperable advanced cholangiocarcinomasMedDRA version: 19.0 Level: LLT Classification code 10008594 Term: Cholangiocarcinoma non-resectable System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-002888-10-LTPCI Biotech AS61